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Introduction: The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a
monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor, in rheumatoid arthritis
(RA) patients.
Methods: Patients with RA who completed one of two 24-week randomized controlled trials (RCTs) participated in
this 52-week, flexible-dose, open-label extension study. Patients in RCT1 received intravenous placebo, 30-mg
tabalumab or 80-mg tabalumab every 3 weeks, and patients in RCT2 received subcutaneous placebo or 1-, 3-,
10-, 30-, 60- or 120-mg tabalumab every 4 weeks (Q4W). Regardless of prior treatment, all patients in this study
received subcutaneous 60-mg tabalumab Q4W for the first 3 months, then a one-time increase to 120-mg
tabalumab Q4W (60-mg/120-mg group) and a one-time decrease to 60-mg tabalumab Q4W per patient was
allowed (60-mg/120-mg/60-mg group).
Results: There were 182 patients enrolled: 60 mg (n = 60), 60/120 mg (n = 121) and 60/120/60 mg (n = 1).
Pretabalumab baseline disease activity was generally higher in the 60-mg/120-mg group. There was a higher
frequency of serious adverse events and treatment-emergent adverse events, as well as infections and injection-site
reactions, in the 60-mg/120-mg group. One death unrelated to the study drug occurred (60-mg/120-mg group).
In both groups, total B-cell counts decreased by approximately 40% from the baseline level in the RCT originating
study. Both groups demonstrated efficacy through 52 weeks of treatment relative to baseline pretabalumab disease
activity based on American College of Rheumatology criteria improvement ≥20%, ≥50% and ≥70%; European
League against Rheumatism Responder Index in 28 joints; Disease Activity Score in 28 joints–C-reactive protein; and
Health Assessment Questionnaire–Disability Index.
Conclusions: With long-term, open-label tabalumab treatment, no unexpected safety signals were observed, and
B-cell reductions were consistent with previous findings. Despite differences in RCT originating studies, both groups
demonstrated an efficacy response through the 52-week extension.
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B-cell-activating factor (BAFF) is a novel tumor necrosis
family (TNF) family ligand that is necessary for B-cell
survival [1]. Increased BAFF expression is also associated
with autoantibody production and synovitis in rheuma-
toid arthritis (RA) patients [2]. Neutralizing BAFF may
be an effective method of targeting B cells involved in
RA pathogenesis.
Tabalumab is a human anti-BAFF monoclonal antibody
that neutralizes both biologically active forms (membrane-
bound and soluble) of BAFF [3] and has the potential to
reduce RA signs and symptoms in patients in whom con-
ventional treatments have failed [4-6].
This trial was designed to evaluate the long-term
(52-week) safety and efficacy of subcutaneous 60-mg
tabalumab administered every 4 weeks (Q4W), with an
option to increase the dose to 120-mg tabalumab Q4W
after 3 months of treatment, in patients with RA who
had completed ≥24 weeks of participation and received




In this 52-week, flexible-dose, open-label extension (OLE)
study, we enrolled rheumatoid factor and/or anticyclic
citrullinated peptide–seropositive patients with active RA
(American Rheumatism Association 1987 revised criteria
[7]) who had completed one of two phase II, 24-week,
randomized controlled trials (RCTs) according to pro-
tocol. Patients from 14 countries were enrolled (Austria,
Australia, Belgium, Brazil, Canada, Chile, Germany,
Hungary, India, Mexico, Poland, Puerto Rico, Romania
and the United States) [4,5]. Patients were excluded from
participation if they had experienced a safety event during
the prior RCTs that, in the investigators’ opinion, posed
an unacceptable risk or if they had received any drug not
allowed by the RCT protocol (ClinicalTrials.gov Identifier:
NCT00837811). The study was approved by the local in-
stitutional review boards (see Additional file 1) in accord-
ance with the Declaration of Helsinki and applicable laws
and regulations. All patients provided voluntary written
informed consent.
Patients enrolled in the first RCT (RCT1) were TNF an-
tagonist inadequate responders (TNF-IR) who received
placebo, 30-mg tabalumab or 80-mg tabalumab intraven-
ously every 3 weeks for 6 weeks and were followed through
week 24 [4]. During RCT1, patients with <20% improve-
ment in tender or swollen joint counts (28 joints) by week
16 were given the option to receive an 80-mg tabalumab
rescue dose at week 16. Patients enrolled in the second
RCT (RCT2) were methotrexate inadequate responders
(MTX-IR) who received placebo or 1-, 3-, 10-, 30-, 60- or
120-mg tabalumab subcutaneously Q4W for 24 weeks [5].All patients were on a stable background dose of metho-
trexate. During the OLE study, all patients received 60-mg
subcutaneous tabalumab Q4W for 48 weeks, regardless of
prior treatment (that is, tabalumab or placebo arm, dose
of study drug or route of administration) (Figure 1). After
3 months of 60-mg tabalumab Q4W, each patient was
allowed a one-time increase to 120-mg tabalumab Q4W
based on the investigators’ clinical judgment and if the pa-
tient had at least four tender and at least four swollen
joints. A one-time decrease to 60-mg tabalumab Q4W
was allowed, but no further adjustments could be made.
Assessments
Safety assessments included incidences of treatment-
emergent adverse events (TEAEs), serious adverse events
(SAEs) and assessments of vital signs, clinical laboratory
data and immunogenicity. Blood samples were collected
for determination of serum tabalumab concentrations and
measures of biologic activity. Serum samples were taken
after dose adjustments (increase to 120 mg or decrease to
60 mg). Measures of biologic activity included changes in
C-reactive protein (CRP), total B cells (CD20 + CD3−),
B-cell subsets (immature (CD19 + CD27 − IgD−), mature
naïve (CD19 + CD27 − IgD+), switched memory (CD19 +
CD27 + IgD−) and immunoglobulins (IgG, IgM and IgA).
Infection rates and any association between infections and
changes in B cells or immunoglobulins were also assessed.
Long-term efficacy was assessed at 24 and 52 weeks ac-
cording to the proportion of patients with an American
College of Rheumatology criteria improvement ≥20%
(ACR20), ≥50% (ACR50) or ≥70% (ACR70), as well as on
the basis of the ACR-N Index. Additional efficacy mea-
sures included the Health Assessment Questionnaire–
Disability Index (HAQ-DI), the European League against
Rheumatism Responder Index in 28 joints (EULAR28)
and the Disease Activity Score in 28 joints (DAS28)–CRP.
Statistical analyses
Safety analyses included all patients who received study
drug. All efficacy and biologic activity analyses were con-
ducted on an intent-to-treat basis and included patients
who received at least one dose of study drug and had at
least one postbaseline value. For ACR20, ACR50 and
ACR70 analyses, patients who discontinued the study
drug prior to week 52 were imputed as nonresponders
(NRI; n = 34); otherwise, the last observed components
of the index were utilized for each patient’s response
(last observation carried forward (LOCF)). For HAQ-DI,
EULAR28 and DAS28-CRP, the LOCF approach was
used. Pharmacokinetic profiles were simulated, and a
90% prediction interval was created using the final mo-
del derived from RCT1 and RCT2 data. Graphical ana-
lysis was used for comparison of the model predictions
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Figure 1 Randomized controlled trial and open-label extension study designs. aNonresponders (<20% improvement in tender or swollen
joint counts in 28 joints) were eligible to receive an additional 30-minute infusion of 80-mg tabalumab as a rescue dose at week 16. IV, Intravenous;
MTX-IR, Methotrexate inadequate responders; n, Number of patients per treatment arm; N, Total number of patients enrolled; RCT, Randomized
controlled trial; SC, Subcutaneous; TNF-IR, Tumor necrosis factor inadequate responders.
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one patient in the 60-mg group had no postbaseline
B-cell data. These patients were not included in B-cell
analyses. One patient in the 60-mg/120-mg group was
not included in absolute B-cell analyses because of an
erroneous lab result that was not consistent with the
patient’s absolute lymphocyte or absolute CD19 B-cell
count. Two patients were excluded from efficacy ana-
lyses: one patient (60 mg) had no postbaseline efficacy
data and was lost to follow-up, and one patient (60 mg/
120 mg) was removed because of good clinical practice
violations.
The expected maximum sample size was 249 patients.
This sample size was not based on statistical consi-
derations; it was expected that between 5% and 25% of
patients from the originating studies would not elect to
participate in the OLE study. Assuming 200 participants,
the probability of observing at least one adverse event
(AE) of a specific type is 0.866 when the background AE
rate for the event is 1% in a similar cohort of patients
during the time frame of this study.Baseline data for demographics, clinical characteristics,
biologic activity and efficacy measures were summarized
from data collected before patients received the active
drug in RCT1, RCT2 or the OLE study (that is, preta-
balumab baseline). For patients assigned to receive taba-
lumab in RCT1 or RCT2, pretabalumab baseline data
were collected at week 0 of the originating study. For pa-
tients assigned to receive placebo in RCT1 or RCT2,
pretabalumab baseline data were collected either before
receiving an optional 80-mg tabalumab rescue dose at
week 16 in RCT1 or at OLE study entry. Data were de-
scriptively summarized by treatment for all safety assess-
ments at the endpoint and for biologic activity measures
and efficacy measures at each visit.
Results
Patient disposition
Of the 186 eligible patients who completed RCT1 or
RCT2, 98% (N = 182) were enrolled in the OLE study.
Patients were evaluated within two different treatment
groups: a 60-mg group (n = 60 comprising patients who






(N = 60) (N = 121)
Males, n (%) 9 (15) 22 (18)
Age, yr 53 ± 12 52 ± 12
Duration of RA, yr 9 ± 7 10 ± 8
Swollen joint count (28) 10.2 ± 6.5 12.2 ± 6.3
Tender joint count (28) 13.1 ± 8.1 16.1 ± 7.6
Physician’s Global Assessment (VAS) 48 ± 21 57 ± 22
Patient’s Global Assessment of Disease
Activity (VAS)
55 ± 23 63 ± 23
Patient’s Global Assessment of
Pain (VAS)
55 ± 23 60 ± 23
HAQ-DI 1.5 ± 0.7 1.7 ± 0.6
CRP, mg/dl 2.2 ± 1.9 2.3 ± 2.4
DAS28 5.5 ± 1.3 5.9 ± 1.1
Prior TNF exposure, n (%) 17 (28) 58 (48)
Prior HCQ exposure, n (%) 25 (42) 33 (27)
Prior SSZ exposure, n (%) 14 (24) 36 (30)
Weekly dose of MTX, mg 16 ± 4 16 ± 5
Daily dose of prednisone dose, mg 7 ± 3 7 ± 3
Concomitant prednisone, n (%) 38 (64) 92 (76)
aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HAQ-DI,
Health Assessment Questionnaire–Disability Index; HCQ, Hydroxychloroquine;
MTX, Methotrexate; RA, Rheumatoid arthritis; RCT, Randomized control trial;
SSZ, Sulfasalazine; TNF, Tumor necrosis factor; VAS, Visual analogue scale. Data
are mean ± SD unless noted otherwise. For patients assigned to receive
tabalumab in RCT1 or RCT2, pretabalumab baseline data were collected at
week 0 of RCT1 or RCT2. For patients assigned to receive placebo in RCT1 or
RCT2, pretabalumab baseline data were collected either before patients
received an optional 80-mg tabalumab rescue dose at week 16 in RCT1 or at
open-label extension study entry. Numbers in bold denote pretabalumab RA
activity levels that were greater for the 60-mg/120-mg tabalumab group
compared to the 60-mg tabalumab group.
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lated) and a 60-mg/120-mg group (n = 121, comprising
patients whose dose was escalated from 60-mg to 120-mg
tabalumab). The dose was escalated at week 12 for most
patients (84 (69%) of 121) in the 60-mg/120-mg group.
For one additional patient, the dose was escalated from
60 mg to 120 mg and then returned to 60 mg (60-mg/
120-mg/60-mg group); this patient is not reported here.
Overall, 146 (80%) of 182 patients completed 52 weeks
of treatment and 36 patients (20%) discontinued early.
The most common reasons (≥5% of patients in either
group) for early discontinuation were lack of efficacy
(60 mg: 0%, 60 mg/120 mg: 9%), AEs (60 mg: 5%,
60 mg/120 mg: 5%) and patient’s decision (60 mg: 2%,
60 mg/120 mg: 6%).
Baseline characteristics
Pretabalumab baseline RA activity levels were generally
higher in the 60-mg/120-mg group (Table 1). Patients in
whom the dose was escalated to 120 mg (60-mg/120-mg
group) were found to have higher pretabalumab baseline
values for the individual ACR criteria components (that
is, tender and swollen joint counts, patient’s assessments
of pain and disease activity and physician’s assessment of
pain). The HAQ-DI, DAS28-CRP and CRP values were
also observed to be slightly higher in the 60-mg/120-mg
group than in the 60-mg group.
Pharmacokinetics
Sample collection times and dosing regimens/history in
the OLE study were considered to appropriately compare
the data with pharmacokinetic profile model predictions.
The mean number of tabalumab doses was comparable
in the 60-mg and 60-mg/120-mg groups. During the
OLE study, pharmacokinetic concentrations of tabalumab
closely aligned with RCT1 and RCT2 model predictions
(data not shown).
Immunopharmacologic and disease-related biologic
activity
Pretabalumab mean baseline CRP values were not sig-
nificantly different in the 60-mg and 60-mg/120-mg
group (2.2 ± 1.9 mg/dl and 2.3 ± 2.4 mg/dl, respectively)
(Table 1). During the course of 52 weeks, mean (stan-
dard deviation (SD)) CRP values decreased in the 60-mg
and 60-mg/120-mg groups (week 24: 1.4 ± 1.4 mg/dl
and 2.2 ± 2.6 mg/dl; week 52: 1.3 ± 1.6 mg/dl and 1.6 ±
1.6 mg/dl, respectively). Median percentage changes in
CRP from pretabalumab baseline in the 60-mg and 60-mg/
120-mg groups, respectively, were −43% and −19% at week
24 and −47% and −29% at week 52.
In all groups, total mature B-cell (CD20 + CD3−) and
mature naïve B-cell (CD19 + CD27 − IgD+) counts gra-
dually declined over time, but were not totally depletedat week 52 (Figures 2A and 2C). Immature (CD19 +
CD27 − IgD−) and switched memory (CD19 + CD27 +
IgD−) B-cell counts initially increased from pretabalumab
baseline at week 12, followed by a gradual decline over
time without total depletion at week 52 (Figures 2B and
2D). Switched memory (CD19 + CD27 + IgD−) B cells in-
creased about 100% over baseline of the RCT originating
study at week 12, then declined to approximately 60% to
70% over baseline values at week 52 (Figure 2D). Low total
B-cell counts were defined as at least one B-cell assess-
ment below 43 cells/μl and <50% of the pretabalumab
baseline value. Of the 66 patients (36%) who completed
52 weeks of treatment and had low total B-cell counts, 49
completed follow-up and recovered by week 114, 66 weeks
after the last injection. Recovery was defined as an abso-
lute B-cell count ≥43 cells/μl or ≥50% of pretabalumab
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Figure 2 Mean percentage changes in B cells and B-cell subsets. Mean percentage changes in total mature (CD20 + CD3−) (A), immature
(CD19 + CD27 − IgD−) (B), mature naïve (CD19 + CD27 − IgD+) (C) and switched memory (CD19 + CD27 + IgD−) (D) B cells are shown. The week
0 comparison is of the B cells to pretabalumab baseline counts before dosing with tabalumab. For patients who received tabalumab in the first
or second randomized controlled trial, the pretabalumab baseline count represents B-cell count at a time point prior to week 0 of this open-label
extension study. All patients were required to have B-cell follow-up through week 72; only patients who did not meet the definition of recovery
were required to have follow-up beyond week 72. Data after week 100 are not shown, as there were fewer than five patients per arm. Ig, immunoglobulin;
N, Number of patients per treatment arm; n, number of patients assessed at a given time point.
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patients was 40.6 weeks (confidence interval: 39.6 to 51.3).
At the start of open-label treatment, both the 60-mg
and 60-mg/120-mg groups showed a decline of 11% or
less from their pretabalumab baseline serum immuno-
globulin levels (IgG, IgM and IgA). At weeks 24 and 52,
serum IgG, IgM and IgA continued to decrease from
pretabalumab baseline for both groups (Figure 3). At
week 36, the 60-mg group showed a more pronounced
decrease in IgA levels than was observed in the 60-mg/
120-mg group.
Treatment-emergent immunogenicity was defined as a
fourfold increase from baseline titer or an increase of at
least two dilutions during the treatment or follow-up
period. Over the course of 52 weeks, 17 (9%) of 182 pa-
tients developed treatment-emergent antidrug antibodies
(TEAbs); none were neutralizing. Persistent TEAb (posi-
tive antidrug antibody (ADA) detected at two or more
sequential sample times with ≥12 weeks between the
first and last samples or a positive ADA at the lastobtained sample and no opportunity to assess persis-
tence) was identified in 11 patients (6%). Two patients
had persistent TEAb in RCT2 and remained positive
for ≥12 weeks in the OLE study. Seven patients (4%) had
follow-up emergent ADA (positive in the follow-up
period only), and six were persistently positive. Plasma
concentrations of patients who met TEAb criteria with
tabalumab-specific ADA were compared to those of pa-
tients without ADA. Patients in the OLE study who had
transient or persistent ADA had concentrations similar
to those of patients without ADA and similar to the pre-
diction interval (data not shown). The presence of ADA
had minimal or no effect on the serum pharmacokinetics
of tabalumab over the 52-week course of treatment.
Safety
Three patients (5%) in the 60-mg group and six patients
(5%) in the 60-mg/120-mg group discontinued during the
OLE study because of an AE. In the 60-mg group, these
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Figure 3 Mean percentage changes in immunoglobulins. Mean percentage changes in immunoglobulin G (A), immunoglobulin M (B), and
immunoglobulin A (C) are shown. The week 0 comparison is of the immunoglobulins to baseline counts before dosing with tabalumab. For
patients receiving tabalumab in the first or second randomized controlled trial, the baseline count represents the immunoglobulin level at a time
point prior to week 0 of this open-label extension study. Data after week 100 are not shown, as there were fewer than five patients per arm.
Ig, Immunoglobulin; N, Number of patients per treatment arm; n, Number of patients assessed at a given time point.
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60-mg/120-mg group, these events were intervertebral
discitis, osteomyelitis, worsening of RA, breast cancer,
cerebrovascular accident and pulmonary fibrosis (reported
by one patient each).
A total of 133 AEs were reported for 182 patients (73%).
The exposure-adjusted rates of TEAEs were 111/100
patient-years (PYs) for all patients while receiving 60-mg
tabalumab and 118/100 PYs for all patients while receiving
120-mg tabalumab. The overall incidences of TEAEs were
also higher in the 60-mg/120-mg group (79%) than in the
60-mg group (63%). Overall, the most frequently (≥5%)
reported TEAEs were infection, RA worsening and injec-
tion-site reaction. The frequencies of these events in the
60-mg and 60-mg/120-mg groups, respectively, were in-
fections (37% and 48%, respectively), RA worsening (18%
and 25%, respectively) and injection-site reactions (3%
and 12%, respectively). The exposure-adjusted rates ofinfection were 53/100 PYs for all patients while receiving
60-mg tabalumab and 62/100 PYs in all patients while re-
ceiving 120-mg tabalumab. Overall, the most frequently
reported infection types were upper respiratory infections
(URIs) and urinary tract infections (UTIs). URIs (including
MedDRA (Medical Dictionary for Regulatory Activities)
high-level terms: laryngitis, nasopharyngitis, pharyngitis,
pharyngotonsillitis, rhinitis, sinusitis and URI) were re-
ported with the same frequency in the 60-mg group (25%)
and the 60-mg/120-mg group (25%). UTIs were reported
in 3% of patients in the 60-mg group and 11% in the
60-mg/120-mg group. One patient (60-mg/120-mg group)
reported a nonserious AE of fungal skin infection. Among
patients with decreases in B cells (>50% reduction from
pretabalumab baseline), the number of infections reported
per person was similar to that of patients whose B cells
did not fall below 50% of pretabalumab baseline (Table 2).
Patients with reductions in serum IgG, IgM and IgA that
Table 2 Percentage of patients with at least one infection
during the treatment perioda
n/N (%)
60 mg (N = 60) 60 mg/120 mg (N = 121)
B cells, cells/μl
>50% reduction 10/38 (26%) 29/66 (44%)
≤50% reduction 9/16 (56%) 21/42 (50%)
No reduction 3/5 (60%) 6/10 (60%)
Serum IgG
≥5.65 g/L 22/58 (38%) 56/118 (48%)
<5.65 to ≥4.24 g/L 0/1 (0%) 2/2 (100%)
<4.24 g/L 0/0 (0%) 0/1 (0%)
Serum IgM
≥0.40 g/L 22/57 (39%) 55/113 (49%)
<0.40 to ≥0.30 g/L 0/2 (0%) 1/4 (25%)
<0.30 g/L 0/0 (0%) 2/4 (50%)
Serum IgA
≥0.70 g/L 22/59 (37%) 58/120 (48%)
<0.70 to ≥0.525 g/L 0/0 (0%) 0/0 (0%)
<0.525 g/L 0/0 (0%) 0/1 (0%)
aIg, Immunoglobulin; n, Number of patients with at least one infection with
analyte measurement in that category; N, Number of patients with analyte
measurement in that category; RCT, Randomized control trial. For patients
assigned to receive tabalumab in the first or second randomized controlled
trial (RCT1 or RCT2, respectively) pretabalumab baseline data were collected at
week 0 of RCT1 or RCT2. For patients assigned to receive placebo in RCT1 or
RCT2, pretabalumab baseline data were collected either before receiving an
optional 80-mg tabalumab rescue dose at week 16 in RCT1 or at the time of
open-label extension study entry.
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higher number of infections compared to patients with no
reductions in the same serum immunoglobulins.
SAEs also occurred more frequently in the 60-mg/
120-mg group (13%) than in the 60-mg group (7%). In the
60-mg group, five SAEs occurred in four patients: myo-
cardial ischemia and postprocedural hemorrhage (experi-
enced by the same patient), RA worsening, hepatitis A
infection and hip prosthesis dislocation. In the 60-mg/
120-mg group, 21 SAEs occurred in 16 patients: hy-
pertrophic cardiomyopathy; gastric ulcer; myocardial in-
farction; viral gastroenteritis and diabetic ketoacidosis
(experienced by the same patient); intervertebral discitis
and psoas abscess (experienced by the same patient);
osteomyelitis; pneumonia; brain contusion, fall resulting
in injury and RA worsening (experienced by the same pa-
tient); osteonecrosis and arteriosclerosis (experienced by
the same patient); benign lung neoplasm and pulmonary
fibrosis (experienced by the same patient); breast cancer;
and cerebrovascular accident. Pulmonary fibrosis was re-
ported in one additional 60-mg/120-mg patient, and RA
worsening was reported in three additional 60-mg/120-mg patients. The one patient whose dose was esca-
lated from 60 mg to 120 mg and then returned to 60 mg
experienced mild pancytopenia and an ischemic stroke
(reported on separate visits) during the 52-week treatment
period.
One patient in the 60-mg/120-mg group died due to
myocardial infarction (reported above as an SAE). The
patient had received the first dose of study drug 182 days
prior, was compliant with concomitant medications and
had no history of coronary artery disease or cardiovascu-
lar disease other than hypertension and atherosclerosis.
The investigator deemed the event not to be related to
the study drug.
No notable differences or trends were identified in vital
signs, electrocardiograms (ECGs) or chemistry, hematology
and urinalysis panels. At the start of open-label treatment,
the majority of patients in the 60-mg group (93%) and
60-mg/120-mg group (93%) had normal lymphocyte
values; a small percentage had values that were low
(60 mg = 3%, 60 mg/120 mg = 6%) or high (60 mg = 3%,
60 mg/120 mg = 1%). By week 52, lymphocyte values were
in the normal range for 86% of the 60-mg and 88% of the
60-mg/120-mg patients. Relative to baseline, more pa-
tients had low lymphocyte values (60 mg = 11%, 60 mg/
120 mg = 7%) at week 52.
Clinical response
Both treatment groups demonstrated efficacy with
52 weeks of tabalumab treatment. The ACR20, ACR50
and ACR70 response rates in the 60-mg group at week 24
(observed; ACR20 = 70%, ACR50 = 36%, ACR70 = 13%)
were generally maintained by week 52 (NRI/LOCF;
ACR20 = 66%, ACR50 = 34%, ACR70 = 19%) (Figure 4A).
Similarly, the ACR20, ACR50 and ACR70 response rates
in the 60-mg/120-mg group at week 24 (ACR20 = 41%,
ACR50 = 20%, ACR70 = 5%) were generally maintained
by week 52 (NRI/LOCF; ACR20 = 33%, ACR50 = 13%,
ACR70 = 7%) (Figure 4B). The mean (±SD) ACR-N in the
60-mg group was similar at week 24 (28.7 ± 53.6) and
week 52 (31.9 ± 47.6). However, for the 60-mg/120-mg
group, the mean (±SD) ACR-N was −8.9 ± 126.7 at week
24 (these patients were rescued during this period and
dose-escalated). In this 60-mg/120-mg group, the ACR-N
response improved to 11.3 ± 46.4 at week 52.
TNF-IR patients who originated from RCT1 had ACR20,
ACR50 and ACR70 response rates of 40%, 17% and 6%, re-
spectively, at week 24. Clinical improvement as measured
by ACR response rates were observed for some patients at
week 52 (based on NRI; ACR20 = 29%, ACR50 = 13%,
ACR70 = 7%). MTX-IR patients who originated from
RCT2 had ACR20, ACR50 and ACR70 response rates of
51%, 28% and 8%, respectively, at week 24. This response
was maintained at week 52 (based on NRI; ACR20 = 52%,
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Figure 4 Response rates on various efficacy parameters. (A) and (B) ACR20, ACR50 and ACR70 response rates at week 24 (observed) and week
52 (NRI) for the 60-mg tabalumab group and the 60-mg/120-mg tabalumab group, respectively. (C) and (D) The EULAR28 (good +moderate) response
rates for the 60-mg tabalumab and 60-mg/120-mg tabalumab groups, respectively, at week 24 (observed) and week 52 (LOCF). ACR, American College
of Rheumatology Responder Index; EULAR28, European League against Rheumatism Responder Index based on 28 joints; LOCF, Last observation
carried forward; n, Number of responders; N, Number of patients per treatment arm; NRI, Imputed as nonresponders; Wks, Weeks.
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was achieved by the majority of patients in the 60-mg
group (47 of (84%) of 56) and the 60-mg/120-mg group
(65 (56%) of 117) (Figures 4C and 4D). Reductions on the
HAQ-DI (mean ± SD) from pretabalumab baseline were
similar for the 60-mg group at week 24 (−0.25 ± 0.53) and
week 52 (−0.27 ± 0.53) and for the 60-mg/120-mg group
at week 24 (−0.26 ± 0.56) and week 52 (−0.30 ± 0.62).
Reductions in DAS28-CRP scores (mean ± SD) from pre-
tabalumab baseline were consistent over the course of
52 weeks of treatment in the 60-mg group (week 24: −2.0 ±
1.5, week 52: −2.1 ± 1.5) and the 60/120-mg group (week
24: −1.2 ± 1.4, week 52: −1.3 ± 1.5).
Discussion
In this 52-week OLE study, we evaluated the long-term
safety and efficacy of subcutaneous tabalumab in RA pa-
tients who had completed one of two RCTs.
Long-term tabalumab treatment resulted in gradual
declines in total B cells without total depletion. Declines
in mature naïve B-cell and immature B-cell subsets were
also observed, whereas switched memory B cells initially
increased from baseline of the RCT originating study
and then declined by week 52. The majority of patientswith low B cells at week 52 completed follow-up, and all
patients who completed follow-up recovered. Median
time to recovery after last injection was 40 weeks. There
were no differences between dose groups in observed
immunoglobulin reductions, except at week 36, when
the 60-mg group showed a more pronounced decrease
in IgA levels than the 60-mg/120-mg group. There was
no indication that reductions in B cells or in serum im-
munoglobulins below the lower limit of normal were
associated with an increased frequency of infections.
Overall, these B-cell findings are consistent with taba-
lumab’s mechanism of action and the results of prior
tabalumab studies. Other B-cell-targeted therapies, such
as belimumab and atacicept, have been shown to reduce
B cells incompletely [8,9], whereas, in contrast to the
findings in the present study, rituximab has been shown
to reduce CD19+ B cells to 0, often for months to
years [10].
Tabalumab serum concentrations aligned closely with
RCT1- and RCT2-derived model predictions, sugges-
ting time-independent pharmacokinetics during the OLE
study. Additionally, tabalumab treatment was associated
with a low incidence of ADA, and none of the antibodies
were positive in the neutralizing antibody assay, nor
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or the occurrence of AEs.
No unexpected safety signals were observed in this
study, and slightly higher frequencies of TEAEs and
SAEs were observed in the 60/120-mg than the 60-mg
group. The higher frequency in the 60/120-mg group
may be attributed to a dose–response effect. Overall, the
frequency of TEAEs (range, 63% to 79%) and the fre-
quency of SAEs (range, 7% to 13%) were consistent with
other OLE studies of RA treatments such as belimumab,
tocilizumab and abatacept [9,11,12]. In the present OLE
study, exposure-adjusted rates of TEAEs were lower
than rates reported for other biologics used to treat RA,
although data in the previous studies were summarized
from a greater number of PYs [13,14].
Over the course of 52 weeks of treatment, the results
obtained for RA patients in both groups demonstrated
efficacy on various measures of disease activity, inclu-
ding ACR20, ACR50, ACR70, EULAR28, DAS28-CRP
and HAQ-DI. In the 60-mg/120-mg group, differences
on the ACR-N from week 24 to week 52 that may be at-
tributed to dose adjustment were noted, as the dose for
the majority of these patients was increased from 60-mg
to 120-mg tabalumab at week 12. In general, the dose
given to patients with higher disease activity levels at
pretabalumab baseline was escalated from 60 to 120 mg
relative to patients whose dose was never escalated.
Interpretation of the efficacy and safety of tabalumab
based on this study is limited by the absence of a control
group, by small sample sizes (especially during B-cell
follow-up) and by the heterogeneous population (TNF-
IR and MTX-IR) who were on background methotrexate
as well as other background medications in some in-
stances. Additionally, the extent of tabalumab exposure
varied, as patients were enrolled from two different
RCTs involving a range of doses, dosing regimens and
administration routes.Conclusion
Despite prior treatment differences, efficacy responses
were observed in both groups with up to 52 weeks of
open-label tabalumab treatment. Although a higher fre-
quency of SAEs and severe TEAEs were observed in the
60-mg/120-mg group, no unexpected safety signals were
observed and the frequencies of these events were within
ranges reported for other biologics used to treat RA
[9,11-14]. The reductions in total B cells were consistent
with those observed in prior tabalumab studies. After
this study was completed, phase III clinical trials were
undertaken using tabalumab in RA patients. These trials
were discontinued after interim analyses produced re-
sults that did not meet efficacy expectations [15,16]. No
safety concerns were noted.Additional file
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